BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/22/2024 11:33:24 AM | Browse: 133 | Download: 608
 |
Received |
|
2023-12-30 22:29 |
|
Peer-Review Started |
|
2023-12-30 22:29 |
|
First Decision by Editorial Office Director |
|
2024-01-23 05:01 |
|
Return for Revision |
|
2024-01-23 22:36 |
|
Revised |
|
2024-02-18 13:26 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-04-03 01:38 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-04-03 07:02 |
|
Articles in Press |
|
2024-04-03 07:02 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-05-11 02:54 |
|
Publish the Manuscript Online |
|
2024-05-22 11:33 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Chencheng Xie, Naim Alkhouri and Mohamed A Elfeki |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mohamed A Elfeki, MD, MSc, Assistant Professor, Department of Internal Medicine, University of South Dakota Sanford School of Medicine, 1315 S Cliff Ave, Plaza 3, Suite 1200, Sioux Falls, SD 57105, United States. m_elfiky@hotmail.com |
| Key Words |
Metabolic dysfunction-associated steatotic liver disease; Metabolic dysfunction-associated steatohepatitis; Glucagon-like peptide-1; Glucose-dependent inulinotropic polypeptide; Glucagon; Incretin; Receptor agonist |
| Core Tip |
In this review, we highlight the evolving role of incretin and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease. These agents showed promising potential for improving hepatic steatosis and metabolic dysfunction-associated steatohepatitis (MASH) with a clear benefit for associated cardiometabolic risk factors. However, its role in MASH-associated fibrosis remains unclear. Barriers to access due to limited supplies, cost, and lack of insurance coverage could be overcome through patent and regulatory reforms on drug-device combinations, which may allow for generic competitors of these agents to be available for patients at affordable prices. |
| Publish Date |
2024-05-22 11:33 |
| Citation |
Xie C, Alkhouri N, Elfeki MA. Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges. World J Hepatol 2024; 16(5): 731-750 |
| URL |
https://www.wjgnet.com/1948-5182/full/v16/i5/731.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v16.i5.731 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
